[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337705-105":59,"doc-detail-337705-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","antitumor-activity-of-genetically-engineered-nk-cells-in-nonhematological-solid-tumor-a-comprehensive-review","Antitumor activity of genetically engineered NK-cells in nonhematological solid tumor - a comprehensive review","","Recent advancements in genetic engineering enable modification of natural killer (NK) cells to improve their ability to combat cancers, including solid tumors. This comprehensive review summarizes the current status of genetically engineered chimeric antigen receptor (CAR) NK-cell therapies and their potential in treating solid tumors. It outlines NK cell biology in immune regulation and tumor surveillance, evaluates engineering strategies for efficacy and safety, and highlights clinical translation considerations. CAR-NK cells are discussed as effective against nonhematological malignancies with low graft-versus-host disease risk, while challenges such as off-target effects, immune escape, and manufacturing scalability are addressed with proposed solutions.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/antitumor-activity-of-genetically-engineered-nk-cells-in-nonhematological-solid-tumor-a-comprehensive-review/337705/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/antitumor-activity-of-genetically-engineered-nk-cells-in-nonhematological-solid-tumor-a-comprehensive-review/337705.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the focus of the review on genetically engineered NK cells?","Question",{"text":113,"@type":114},"The review focuses on how genetic engineering can modify NK cells, particularly CAR-NK therapies, to improve antitumor activity against nonhematological solid tumors.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why are NK cells considered suitable for CAR engineering?",{"text":118,"@type":114},"The review highlights NK cells’ low graft-versus-host disease potential and their rarity of causing significant toxicities, making them an attractive platform for CAR engineering.",{"name":120,"@type":111,"acceptedAnswer":121},"What challenges are discussed for clinical translation of engineered NK-cell therapies?",{"text":122,"@type":114},"The review addresses challenges including off-target effects, immune escape mechanisms, and manufacturing scalability, and it describes strategies such as combination therapies and delivery optimization.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},337705,1790738446,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Review  \nPUBLISHED 17 April 2024  \nDOI 10.3389/fimmu.2024.1390498  \nOPEN ACCESS  \nEDITED BY  \nSukh Mahendra Singh, Banaras Hindu University, India  \nREVIEWED BY  \nAlbino Bacolla,  \nUniversity of Texas MD Anderson Cancer Center, United States  \nAjay Kumar,  \nBanaras Hindu University, India  \n*CORRESPONDENCE Manju Jain  \n [manju.jain@cup.edu.in](manju.jain@cup.edu.in)[ ](manju.jain@cup.edu.in)Aklank Jain  \n [aklankjain@gmail.com](aklankjain@gmail.com)  \n†These authors have contributed equally to this work  \nRECEIVED 23 February 2024  \nACCEPTED 18 March 2024  \nPUBLISHED 17 April 2024  \nCITATION  \nDash CP, Sonowal D, Dhaka P, Yadav R, Chettri D, Satapathy BP, Sheoran P, Uttam V, Jain M and Jain A (2024) Antitumor activity of genetically engineered NK-cells in nonhematological solid tumor:  \na comprehensive review.  \nFront. Immunol. 15:1390498 .  \ndoi: 10.3389/fimmu.2024.1390498  \nCOPYRIGHT  \n© 2024 Dash, Sonowal, Dhaka, Yadav, Chettri, Satapathy, Sheoran, Uttam, Jain and Jain. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAntitumor activity of genetically engineered NK-cells in nonhematological solid tumor: a comprehensive review  \nChinmayee Priyadarsini Dash 1†, Dhruba Sonowal 1†, Prachi Dhaka 1†, Rohit Yadav 1, Dewan Chettri 1,  \nBibhu Prasad Satapathy 1, Pooja Sheoran 1, Vivek Uttam 1, Manju Jain 2* and Aklank Jain 1*  \n1 Non-Coding Ribonucleic Acid (RNA) and Cancer Biology Laboratory, Department of Zoology, Central University of Punjab, Bathinda, Punjab, India, 2 Department of Biochemistry, Central University of Punjab, Bathinda, Punjab, India  \nRecent advancements in genetic engineering have made it possible to modify Natural Killer (NK) cells to enhance their ability to fight against various cancers, including solid tumors. This comprehensive overview discusses the current status of genetically engineered chimeric antigen receptor NK-cell therapies and their potential for treating solid tumors . We explore the inherent characteristics of NK cells and their role in immune regulation and tumor surveillance. Moreover, we examine the strategies used to genetically engineer NK cells in terms of efficacy, safety profile, and potential clinical applications. Our investigation suggests CAR-NK cells can effectively target and regress nonhematological malignancies, demonstrating enhanced antitumor efficacy. This implies excellent promise for treating tumors using genetically modified NK cells. Notably, NK cells exhibit low graft versus host disease (GvHD) potential and rarely induce significant toxicities, making them an ideal platform for CAR engineering. The adoptive transfer of allogeneic NK cells into patients further emphasizes the versatility of NK cells for various applications. We also address challenges and limitations associated with the clinical translation of genetically engineered NKcell therapies, such as off-target effects, immune escape mechanisms, and manufacturing scalability. We provide strategies to overcome these obstacles through combination therapies and delivery optimization. Overall, we believe this review contributes to advancing NK-cell-based immunotherapy as a promising approach for cancer treatment by elucidating the underlying mechanisms, evaluating preclinical and clinical evidence, and addressing remaining challenges.  \nKEYWORDS  \nCAR-NK cell therapy, solid tumor, non-hematological tumor, cancer immunotherapy, Genetically engineered CAR-NK cell  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nDespite recent breakthroughs in cancer diagnosis and treatment technologies, canc","cbCairgKEJRm0e41","https://ap.wps.com/l/cbCairgKEJRm0e41","pdf",4663935,18,"English","# Introduction\n## Immunotherapy and NK-cell rationale\n# Current therapeutic landscape for solid cancers\n# Genetically engineered CAR-NK cell approaches\n# Challenges and future perspectives","[{\"question\":\"What is the focus of the review on genetically engineered NK cells?\",\"answer\":\"The review focuses on how genetic engineering can modify NK cells, particularly CAR-NK therapies, to improve antitumor activity against nonhematological solid tumors.\"},{\"question\":\"Why are NK cells considered suitable for CAR engineering?\",\"answer\":\"The review highlights NK cells’ low graft-versus-host disease potential and their rarity of causing significant toxicities, making them an attractive platform for CAR engineering.\"},{\"question\":\"What challenges are discussed for clinical translation of engineered NK-cell therapies?\",\"answer\":\"The review addresses challenges including off-target effects, immune escape mechanisms, and manufacturing scalability, and it describes strategies such as combination therapies and delivery optimization.\"}]","Antitumor activity of genetically engineered NK-cells in nonhematological solid tumor - a comprehensive review | PDF",1790020276,45]